Posaconazole
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Using the report template requirements below, here is the evaluation report generated directly from the Evidence Pack.
Posaconazole: From Invasive Fungal Infection Prophylaxis to Pneumocystosis
One-Sentence Summary
Posaconazole is a triazole antifungal already used for prophylaxis of invasive Aspergillus and Candida infections in high-risk immunocompromised patients (e.g., allogeneic stem-cell transplant / GVHD populations). The TxGNN model predicts it may also be effective against Pneumocystosis (Pneumocystis jirovecii pneumonia), currently supported by 2 clinical trials (both indirect) and 5 publications (mostly guidelines/reviews).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prophylaxis of invasive fungal infections (invasive aspergillosis/candidiasis) in high-risk immunocompromised patients — no formal license text available in this evidence pack |
| Predicted New Indication | Pneumocystosis (Pneumocystis jirovecii pneumonia, PCP) |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L3 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Posaconazole is a triazole antifungal that inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis essential for fungal cell membrane integrity. Although its established use centers on invasive Aspergillus and Candida infections, it also has theoretical activity against Pneumocystis jirovecii, an atypical fungus that shares this same enzymatic target.
In clinical practice, posaconazole is already used off-label/adjacently as prophylaxis against invasive fungal disease — including Pneumocystis pneumonia — in high-risk populations such as allogeneic hematopoietic stem cell transplant recipients and patients with graft-versus-host disease (GVHD). This makes the TxGNN prediction mechanistically plausible: it is less a “novel” repurposing and more a formal recognition of an indication class the drug already touches.
However, posaconazole is not considered standard therapy for active PCP treatment — trimethoprim-sulfamethoxazole (TMP-SMX) remains first-line. The clinical trial and literature evidence currently available reflects this: it largely concerns prophylaxis in transplant/GVHD populations rather than a direct treatment trial of posaconazole against PCP.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04368559 | Phase 3 | Active, not recruiting | 602 | Evaluates IV rezafungin (not posaconazole) vs. standard antimicrobial regimen for prevention of invasive fungal disease in allogeneic transplant recipients. Relevance: Grade C — different drug, same disease area only. |
| NCT06859424 | Phase 2 | Recruiting | 358 | Platform trial comparing GVHD-prophylaxis drug combinations in mismatched unrelated donor transplant recipients — a population where posaconazole is a standard antifungal prophylactic agent. Relevance: Grade B — indirect; posaconazole not the primary study intervention. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41232547 | 2025 | Review/Guideline | Lancet Infect Dis | British Society for Medical Mycology 2025 update on diagnosis of serious fungal disease. |
| 41362140 | 2025 | Review/Guideline | Chin J Tuberc Respir Dis | 2025 Chinese clinical guideline on diagnosis/management of invasive pulmonary fungal disease. |
| 26901377 | 2016 | Review | Swiss Med Wkly | Overview of invasive candidiasis, aspergillosis, cryptococcosis, and PCP; notes posaconazole prophylaxis reduces invasive candidiasis in high-risk hemato-oncology patients. |
| 35596686 | 2022 | Cohort | Transpl Infect Dis | Retrospective review of infectious complications (including fungal) in acute GVHD after liver transplantation. |
| 21973267 | 2011 | Review (PK) | Clin Pharmacokinet | Reviews pulmonary epithelial lining fluid penetration of antifungal agents, including posaconazole. |
EU Market Information
No marketing authorizations are recorded in this evidence pack (total_licenses = 0, market status: Not Marketed). Formal indication text cannot be extracted from local regulatory sources.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: Key warnings, contraindications, and DDI data are all marked as missing in this evidence pack — this is flagged as a Blocking data gap (DG001), meaning a formal safety pre-screen (S1) cannot currently be completed.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L3, but both cited trials are indirect (Grade B/C relevance — neither studies posaconazole as the primary intervention for pneumocystosis), and there is no formal SmPC/warning data available (Blocking gap DG001). The drug also has zero current marketing authorizations in the target jurisdiction. Combined, this is insufficient to move past the research-question stage.
To proceed, the following is needed:
- TFDA/SmPC warnings, contraindications, and DDI data (DG001 — Blocking; source: official label PDF)
- Formal MOA and original indication text via DrugBank API (DG002)
- Direct clinical evidence evaluating posaconazole itself (not surrogate agents like rezafungin) for PCP prophylaxis or treatment efficacy
- Confirmation of regulatory pathway, given the drug is not currently marketed in this jurisdiction
Note: Ranks 3–10 in this prediction set (leprosy, hypertrichosis, Dandy-Walker syndrome, periodontal malformation syndromes, etc.) are flagged by the evidence pack itself as mechanistically implausible (antifungal drug vs. non-fungal/genetic conditions) with no supporting trials or literature — these are model-noise and are already correctly scored L5/Hold and excluded from further consideration.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.